Metallomix develops novel therapies built on its proprietary isotope-selective modulation of metal-dependent biology, beginning with enriched stable zinc isotopes.
Sergei Petukhov, co-founder and CEO of Metallomix, outlines key lessons for biotech startups. He emphasizes assembling a clinical operations team early and maintaining focus on core scientific research. The advice highlights strategic priorities for building a resilient company in the biotech sector.
Metallomix develops disease-modifying drugs using isotopically modified zinc to target solid tumors, neurologic diseases, and metabolic disorders. CEO Sergei Petukhov discusses the company’s metallomics-based approach, which leverages metal-based therapies for precision treatment. The focus lies on repurposing metal chemistry to address unmet medical needs in oncology and neurology.
Nomax Therapeutics advances a novel isotope-selective modulation approach to treat Parkinson’s disease. The company’s founder, Max Temnik, and Chief Medical Officer, Santosh Kesari, lead efforts in this experimental therapy. Nomax has initiated its first-in-human Phase 1 clinical study to assess safety and feasibility.
